A meta-regression analysis of 14 clinical trials, published online in the Journal of Bone and Mineral Research, suggests that treatment-related changes in bone formation markers predict vertebral-fracture reduction with anti-resorptive drug therapy. Drugs that prevent and treat osteoporosis are known to cause short-term changes in bone-turnover markers, and these changes have been linked to subsequent fracture reduction in some studies. The results from this analysis could pave way for the development of new osteoporosis treatments or when considering new populations or dosing regimens with existing treatment.